S?fteland JM, Friman G, von Zur-Mhlen B, et al.. anti-SARS-CoV-2 antibodies after Flavopiridol (Alvocidib) vaccination was Flavopiridol (Alvocidib) associated with more youthful patients, thoracic organ recipients, induction therapy Rabbit polyclonal to A4GNT recipients, and tacrolimus + mycophenolic acid steroids recipients. Conclusions. The immunosuppressive regimen is usually a modifiable predictive factor for humoral response to SARS-CoV-2 vaccine. Several studies have shown that immunocompromised patients, especially solid organ transplant (SOT) patients, have an increased Flavopiridol (Alvocidib) morbidity and mortality in coronavirus disease 19 (COVID- 19).1-4 Lymphopenia was identified as a major risk factor for severe disease in this populace.1,4 Furthermore, in immunocompromised patients who have recovered from COVID-19, the duration of specific antiCsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is unknown but could be reduced.5 Therefore, it is now widely recommended to offer a (SARS-CoV-2 vaccine to SOT patients. However, the humoral response to the SARS-CoV-2 vaccine in this setting is weak, as was previously reported in SOT patients who received the influenza vaccine.6 In fact, weak immunogenicity against SARS-CoV-2, ranging from 10.8% to 17%, 3 or 4 4?wk after the first mRNA vaccine dose has been observed.7,8 In recent series with 23C658 transplant patients, the humoral response to 2 doses of mRNA vaccine ranged from 22% to 58.8%.9-15 Our group recently examined the immunogenicity Flavopiridol (Alvocidib) of the SARS-CoV-2 mRNA-based vaccine in a large cohort of 367 SOT recipients, including kidney, liver, and thoracic transplant patients. Overall, the humoral response at 4?wk after the second vaccine dose was 34%.16 Our aim is to identify the risk factors for humoral response in our cohort of SOT patients. MATERIALS AND METHODS On April 26, 1024 out of 2666 SOT patients at our center experienced received at least 1 vaccine dose. Of these, 393 patients experienced at least 4?wk follow-up after the second dose (288 kidney transplant patients, 65 liver transplant patients, 35 thoracic transplant patients, and 5 isolated pancreas transplant patients). A comparison between patients with 4?wk of follow-up after the second dose and those with insufficient follow-up is presented in Table S1, SDC, http://links.lww.com/TXD/A382. All the patients received an mRNA-based vaccine (BNT162b2 vaccine, Pfizer-BioNTech, n = 391; mRNA-1273 vaccine, Moderna, n = 2). In accordance with the Francophone Transplantation Societys recommendation, patients were asked to participate in biological monitoring, including the antiCSARS-CoV-2 spike protein antibodies before and after vaccination, to assess the security and efficacy of the vaccine. We also retrospectively collected clinical data Flavopiridol (Alvocidib) such as demographic data, the period between transplantation and vaccination, immunosuppressive regimens, and any history of acute rejection. According to French legislation (Loi Jard), anonymous retrospective studies do not require Institutional Review Table approval. Virological Analyses AntiCSARS-Cov-2 spike protein antibody detection was performed using the Wantai total antibody (IgG/IgM/IgA) microplate assay ELISA test (Beijing Wantai Biological Pharmacy Enterprise, Ltd, China) in 80% of the patients.17 The remaining patients were tested with another anti-spike total or immunoglobulin G assay validated by the French National Reference Center. Statistical Analyses Continuous variables are offered as means (SEM). The proportion of patients who developed antibodies is usually reported with exact binomial 95% confidence interval (CI). Proportions were compared by the 2 2 test or Fisher exact test. Quantitative variables were compared by either the Student test or the Mann-Whitney test. Independent factors associated with nonresponse to vaccine were examined with a multivariate logistic regression model that used initial inclusion criteria with a significance of 0.05. A value of 0.05 was considered to be statistically significant. Data analysis was performed using GraphPad Prism version 9.0.2 (GraphPad Software, San Diego, CA) and R (R Foundation for.
